发明名称 USE OF ESSENTIAL OILS TO INCREASE BIOAVAILABILITY OF ORAL PHARMACEUTICAL COMPOUNDS
摘要 A method for increasing bioavailability of an orally administered hydrophobic pharmaceutical compound, which comprises orally administering the pharmaceutical compound to a mammal in need of treatment with the compound concurrently with an essential oil or essential oil component in an amount sufficient to provide bioavailability of the compound in the presence of the essential oil or essential oil component greater than bioavailability of the compound in the absence of the essential oil or essential oil component, wherein the essential oil or essential oil component has an activity of at least 10% inhibition at a concentration 0.01 wt.% or less in an assay that measures reduced conversion of cyclosporine to hydroxylated products using an assay system containing 250 .mu.g rat liver microsomes, 1 .mu.M cyclosporine and 1 mM reduced nicotinamide adenine dinucleotide phosphate (NADPH) in 1 ml of 0.1 M sodium phosphate buffer, pH 7.4.
申请公布号 CA2224227(A1) 申请公布日期 1996.12.19
申请号 CA19962224227 申请日期 1996.06.07
申请人 AVMAX, INC. 发明人 BENET, LESLIE Z.;BENET, REED M.;WACHER, VINCENT J.
分类号 A61K9/00;A61K31/337;A61K36/13;A61K36/14;A61K36/15;A61K36/185;A61K36/23;A61K36/235;A61K36/25;A61K36/28;A61K36/282;A61K36/324;A61K36/328;A61K36/45;A61K36/48;A61K36/53;A61K36/532;A61K36/534;A61K36/537;A61K36/54;A61K36/57;A61K36/61;A61K36/63;A61K36/67;A61K36/738;A61K36/80;A61K36/8962;A61K36/898;A61K36/899;A61K36/9064;A61K36/9068;A61K38/00;A61K38/13;A61K47/10;A61K47/44;(IPC1-7):A61K47/44;A61K45/00 主分类号 A61K9/00
代理机构 代理人
主权项
地址